Michael Ulz Analyst PerformanceExecutive Director at Morgan StanleyMichael Ulz is a stock analyst at Morgan Stanley in the healthcare sector, covering 23 publicly traded companies. Over the past year, Michael Ulz has issued 36 stock ratings, including buy, hold, and sell recommendations. While full access to Michael Ulz's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Michael Ulz's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings77 Last 9 YearsBuy Recommendations77.33% 58 Buy RatingsCompanies Covered23 Unique Companies Ratings Distribution75RatingsDistribution of strong buy, buy, hold, and sell ratings by Michael Ulz.RatingPercentageCount Strong Buy0.0%0 ratings Buy77.3%58 ratings Hold20.0%15 ratings Sell2.7%2 ratingsOut of 75 total stock ratings issued by Michael Ulz at Morgan Stanley, the majority (77.3%) have been Buy recommendations, followed by 20.0% Hold and 2.7% Sell.Best & Worst CallsBest Call0000.0%KYTXApr 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%MRSNAug 2018Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ23 companiesMichael Ulz, an analyst at Morgan Stanley, currently covers 23 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare23 companies100.0%Michael Ulz of Morgan Stanley specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY21 companies91.3%PHARMACEUTICALS2 companies8.7% Michael Ulz's Ratings History at Morgan Stanley Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsMIRMMirum Pharmaceuticals8/6/2026Set Price Target$94.73$137.00$0.0000.00% ROIDYNDyne Therapeutics7/31/2026Lower Price Target$24.83$45.00Overweight$0.0000.00% ROIALNYAlnylam Pharmaceuticals7/31/2026Lower Price Target$202.69$300.00Equal Weight$0.0000.00% ROIKPTIKaryopharm Therapeutics7/31/2026Downgrade$7.01$3.00Neutral$0.0000.00% ROIARWRArrowhead Pharmaceuticals7/23/2026Boost Price Target$87.33$120.00Overweight$0.0000.00% ROIIONSIonis Pharmaceuticals7/10/2026Lower Price Target$59.46$110.00Overweight$0.0000.00% ROIALNYAlnylam Pharmaceuticals7/10/2026Boost Price Target$311.24$400.00Equal Weight$0.0000.00% ROIMIRMMirum Pharmaceuticals6/11/2026Boost Price Target$94.00$150.00Overweight$0.0000.00% ROIAARDAardvark Therapeutics5/15/2026Reiterated Rating$6.73$3.00Underweight$0.0000.00% ROIMIRMMirum Pharmaceuticals5/5/2026Boost Price Target$105.79$140.00Overweight$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. IONSIonis Pharmaceuticals4/21/2026Boost Price Target$74.87$130.00Overweight$0.0000.00% ROIARWRArrowhead Pharmaceuticals4/21/2026Upgrade$69.25$100.00Overweight$0.0000.00% ROIKPTIKaryopharm Therapeutics3/25/2026Lower Price Target$5.44$15.00Outperform$0.0000.00% ROICABACabaletta Bio3/24/2026Lower Price Target$2.70$13.00Overweight$0.0000.00% ROIDYNDyne Therapeutics3/2/2026Lower Price Target$16.03$47.00Overweight$0.0000.00% ROIAARDAardvark Therapeutics3/2/2026Reiterated Rating$12.49$7.00Equal Weight$0.0000.00% ROIIONSIonis Pharmaceuticals2/25/2026Set Price Target$80.93$95.00Overweight$0.0000.00% ROIVIRVir Biotechnology2/24/2026Boost Price Target$7.43$24.00Overweight$0.0000.00% ROIVKTXViking Therapeutics2/12/2026Reiterated Rating$31.92$99.00Overweight$0.0000.00% ROIMIRMMirum Pharmaceuticals1/30/2026Boost Price Target$102.20$123.00Overweight$0.0000.00% ROIALNYAlnylam Pharmaceuticals1/30/2026Lower Price Target$342.09$408.00Equal Weight$0.0000.00% ROIGUTSFractyl Health1/29/2026Downgrade$0.58$2.00Equal Weight$0.0000.00% ROIARWRArrowhead Pharmaceuticals1/7/2026Boost Price Target$65.96$81.00Equal Weight$0.0000.00% ROIKYTXKyverna Therapeutics12/15/2025Set Price Target$10.81$33.00$0.0000.00% ROIMIRMMirum Pharmaceuticals12/9/2025Boost Price Target$67.90$95.00Overweight$0.0000.00% ROIKYTXKyverna Therapeutics12/4/2025Boost Price Target$7.18$25.00Overweight$0.0000.00% ROIARWRArrowhead Pharmaceuticals11/26/2025Boost Price Target$52.39$48.00Equal Weight$0.0000.00% ROIARWRArrowhead Pharmaceuticals11/12/2025Boost Price Target$41.26$45.00Equal Weight$0.0000.00% ROIIONSIonis Pharmaceuticals10/30/2025Boost Price Target$73.80$94.00Overweight$0.0000.00% ROIVKTXViking Therapeutics10/23/2025Boost Price Target$31.42$102.00Overweight$0.0000.00% ROIMIRMMirum Pharmaceuticals10/16/2025Boost Price Target$76.19$81.00Overweight$0.0000.00% ROIIONSIonis Pharmaceuticals10/16/2025Boost Price Target$74.06$90.00Overweight$0.0000.00% ROIKPTIKaryopharm Therapeutics10/9/2025Lower Price Target$5.90$21.00Outperform$0.0000.00% ROIALNYAlnylam Pharmaceuticals10/6/2025Boost Price Target$454.34$475.00Equal Weight$0.0000.00% ROIIONSIonis Pharmaceuticals9/23/2025Boost Price Target$62.85$86.00Overweight$0.0000.00% ROIKPTIKaryopharm Therapeutics8/12/2025Lower Price Target$3.77$25.00Outperform$0.0000.00% ROIRYTMRhythm Pharmaceuticals8/5/2025Reiterated Rating$88.57$109.00Overweight$000.0000.00% ROIALNYAlnylam Pharmaceuticals8/1/2025Boost Price Target$392.24$405.00Equal Weight$000.0000.00% ROIIONSIonis Pharmaceuticals7/31/2025Upgrade$43.37$62.00Overweight$00.0000.00% ROIRYTMRhythm Pharmaceuticals7/9/2025Set Price Target$87.51$95.00Overweight$000.0000.00% ROIBeginner’s Guide to Gold (Ad)The Ultimate Beginner's Guide to Gold IRAs Protect Your Retirement Savings Before It's Too Late With This Informative Guide! Plus, you could even get up to 10% INSTANT MATCH in BONUS Silver (while supplies last).Yes, I Want This Beginner's Guide to Gold IRAs Now!KPTIKaryopharm Therapeutics5/13/2025Lower Price Target$6.15$42.00Outperform$0.0000.00% ROISLNSilence Therapeutics5/9/2025Lower Price Target$3.73$25.00Overweight$0.0000.00% ROIVKTXViking Therapeutics4/24/2025Lower Price Target$25.52$102.00Overweight$00.0000.00% ROIALNYAlnylam Pharmaceuticals4/11/2025Lower Price Target$231.02$268.00Equal Weight$000.0000.00% ROIKYTXKyverna Therapeutics4/1/2025Lower Price Target$1.93$20.00Overweight$0.0000.00% ROICABACabaletta Bio4/1/2025Lower Price Target$1.39$22.00Overweight$0.0000.00% ROIAARDAardvark Therapeutics3/10/2025Initiated Coverage$10.13$29.00Overweight$0.0000.00% ROIYMABY-mAbs Therapeutics3/5/2025Lower Price Target$4.89$7.00Underweight$0.0000.00% ROISLNSilence Therapeutics3/5/2025Lower Price Target$4.38$45.00Overweight$0.0000.00% ROIKPTIKaryopharm Therapeutics3/3/2025Lower Price Target$7.95$54.00Outperform$0.0000.00% ROIIOVAIovance Biotherapeutics2/28/2025Lower Price Target$5.26$20.00Outperform$0.0000.00% ROIALNYAlnylam Pharmaceuticals2/14/2025Boost Price Target$264.89$284.00Equal Weight$000.0000.00% ROITHRDThird Harmonic Bio2/12/2025Downgrade$3.25$5.00Equal Weight$0.0000.00% ROIGUTSFractyl Health2/3/2025Lower Price Target$1.77$10.00Overweight$0.0000.00% ROIAKROAkero Therapeutics1/28/2025Boost Price Target$52.07$96.00Overweight$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenBarclaysRoyal Bank Of CanadaMorgan StanleyJefferies Financial GroupThe Goldman Sachs GroupBMO Capital MarketsSanford C. BernsteinBerenberg BankBNP Paribas ExaneCompass PointPiper SandlerCanadian Imperial Bank of CommerceWeiss RatingsUBS Group Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
